Prezista oral suspension launched

Prezista (darunavir) is now available as a 100mg/ml oral suspension.

Prezista (darunavir) is licensed for use in all adult patients as well as in antiretroviral treatment-experienced paediatric patients aged 3 years and over who weigh at least 15kg
Prezista (darunavir) is licensed for use in all adult patients as well as in antiretroviral treatment-experienced paediatric patients aged 3 years and over who weigh at least 15kg

Prezista (darunavir) is indicated in combination with low dose ritonavir and together with other antiretrovirals for the treatment of HIV-1 infection.

It may be used to administer doses to paediatric patients or in adult patients unable to swallow tablets.

View Prezista drug record

Further information: Janssen-Cilag Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

New restrictions and precautions for use have been...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.